查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1447725

大麻二酚市場評估：按物種、給藥途徑、形式、治療用途、最終用戶和地區劃分的機會和預測（2017-2031）

Cannabidiol Market Assessment, By Species, By Route of Administration, By Form, By Therapeutic Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 227 Pages | 商品交期: 3-5個工作天內

價格

全球大麻二酚市場規模預計將從2023年的80.4億美元成長到2031年的302.2億美元，2024-2031年預測期間複合年增長率為18%，預計規模還將不斷擴大。

全球大麻二酚市場的發展受到多種因素的推動，包括 CBD 在醫療保健行業的藥用用途的擴大以及領先公司增加研發以研究 CBD 在各種醫療條件下的潛在益處。 人們對安全使用 CBD 治療癲癇等健康狀況的接受度不斷提高，這也導致了全球市場的成長。 各國CBD的合法化正在增加公共和私人機構投資大麻二酚市場的興趣。 主要參與者、新創公司和合資企業的存在，以及這些公司的併購、聯盟、分銷協議和頻繁的新產品發布，正在推動全球大麻二酚市場的成長。

由於 CBD 作為治療焦慮、憂鬱、慢性疼痛、癲癇等藥物的廣泛應用，全球大麻二酚市場正在經歷顯著增長。 CBD因其巨大的治療功效潛力而被廣泛應用於製藥業，如CBD油、膠囊和外用乳膏。 因此，一些公共和私人組織正在增加對研發活動的投資，以進一步發現 CBD 的治療益處。 近年來，患者和醫療保健提供者越來越接受 CBD 用於醫療目的，導致 CBD 市場的需求增加。

有利的監管架構在加強全球 CBD 市場方面也發揮著重要作用。 將 CBD 用於醫療目的在各國正在變得合法。 此外，公司之間頻繁的併購和合作協議等合作活動、主要參與者不斷推出創新產品以及新進業者也進一步推動了全球大麻二酚市場的發展。

心理健康問題增加

隨著世界人口中焦慮和憂鬱等精神疾病的數量不斷增加，對大麻二酚的需求激增。 世界衛生組織（WHO）指出，憂鬱症等精神疾病已成為當今生活中常見的健康狀況。 全球約有3.8%的人口患有憂鬱症，其中5%的成年人和5.7%的60歲以上人口患有憂鬱症。

有利的監理架構

隨著對基於 CBD 的產品的需求不斷增長，FDA 等監管機構正在考慮改進並引入新的監管途徑，以支持 CBD 產品在醫學中的道德和安全使用。事實確實如此。 2023年1月，美國FDA宣布將重新評估含有大麻二酚產品的監管架構。

本報告調查了全球大麻二酚市場，提供了市場定義和概述、市場規模趨勢和預測、各個細分市場和地區的詳細分析、行業結構以及影響市場成長的因素分析、案例研究、競爭格局、簡介關鍵公司等。

目錄

第1章研究方法

第 2 章專案範圍與定義

第 3 章執行摘要

第4章全球大麻二酚市場展望

  • 市場規模/預測
  • 生物物種
    • 秈稻
    • 苜蓿
    • 混合動力
  • 依給藥途徑
    • 口頭
    • 本地
    • 其他
  • 依形式
    • 石油
    • 膠囊
    • 酊劑
  • 依治療用途
    • 癌症
    • 偏頭痛
    • 癲癇
    • 焦慮/憂鬱
    • 其他
  • 按最終用戶
    • 製藥公司
    • 醫院藥房
    • 網路藥局
    • 零售店
    • 研發中心
    • 其他
  • 按地區
    • 北美
    • 歐洲
    • 南美洲
    • 亞太地區
    • 中東/非洲
  • 各公司的市佔率

第5章全球大麻二酚市場展望：依地區

  • 北美
  • 歐洲
  • 南美洲
  • 亞太地區
  • 中東/非洲

第 6 章市場映射

  • 依產品類型
  • 依方法
  • 依用途
  • 按最終用戶
  • 按地區

第7章宏觀環境與產業結構

  • 需求與供給分析
  • 匯入/匯出分析
  • 價值鏈分析
  • PESTEL 分析
  • 波特五力分析

第 8 章市場動態

  • 生長促進因素
  • 抑制生長的因素（問題/抑制因素）

第 9 章監理架構與創新

  • 臨床試驗
  • 專利情況
  • 監理機關的核准
  • 創新/新興技術

第10章主要公司狀況

  • 前 5 名市場領導者的競爭矩陣
  • 前 5 位市場領導者的市場收入分析
  • 併購/合資企業（如果適用）
  • SWOT 分析（主要公司）
  • 專利分析（如果適用）

第11章價格分析

第 12 章案例研究

第13章主要公司展望

  • Charlotte's Web, Inc.
  • Medical Marijuana, Inc.
  • Jazz Pharmaceuticals plc.
  • Aurora Cannabis Inc.
  • Hemp Synergistics LLC
  • Canopy Growth Corporation
  • Isodiol International Inc.
  • Gaia Botanicals, LLC, d/b/a Bluebird Botanicals
  • CV Sciences, Inc.
  • High Tide Inc.

第 14 章策略建議

第15章關於我們公司/免責聲明

Product Code: MX11132

Global cannabidiol market is projected to witness a CAGR of 18% during the forecast period 2024-2031, growing from USD 8.04 billion in 2023 to USD 30.22 billion in 2031. The market has experienced significant growth in recent years and is expected to maintain a strong pace of expansion in the coming years.

Growth in the global cannabidiol market is being driven by various factors such as increased medicinal application of CBD in the healthcare industry and increased research and development by leading players to study the potential benefits of CBD in different medical conditions. Growing acceptance among people regarding the safe usage of CBD for health conditions such as epilepsy is leading to the growth of this market globally. Increased legalization of CBD across different countries is enhancing the interest of public and private organizations in investing in the cannabidiol market. The presence of several top players, new companies, and collaborative ventures such as mergers and acquisitions, partnerships, distribution agreements, and frequent new product launches are driving the growth of the global cannabidiol market.

The global cannabidiol market is undergoing significant growth due to the increasing application of CBD for medicinal purposes such as anxiety, depression, chronic pain, and epilepsy. CBD is widely used by the pharmaceutical industry as CBD oils, capsules, and topical creams, due to its huge potential in providing therapeutical advantages. As a result, several public and private organizations are increasingly investing in research and development activities to find out more therapeutical benefits of CBD. Over the years, there has been an increased acceptance of CBD usage for medicinal purposes among patients and healthcare providers, leading to a growing demand for the CBD market.

A favorable regulatory framework plays a crucial role in enhancing the global CBD market. There has been increased legalization of the usage of CBD for medicinal purposes across different countries. The act is enhancing and expanding the CBD market at a global level. Moreover, frequent collaboration activities such as mergers and acquisitions, partnership agreements between the companies, consistent innovative product launches by the key market players, along with new entrances, further propels the global cannabidiol market. In December 2023, Rare Cannabinoid Company announced the launch of THC + THCV Uplift Gummies. This product has been launched for the United States consumers to increase focus, energy, and control hunger.

Increasing Prevalence of Mental Health Problems

There has been a surge in demand for cannabidiol due to the rising number of mental illnesses such as anxiety and depression among the global population. Mental health conditions are not uncommon these days and affect a larger section of people from all over the world. The World Health Organization states that mental disorders such as depression have become a common health condition in today's life. Globally, around 3.8% of the population is affected by depression, includes 5% of adults and 5.7% of people aged 60 years and above.

WHO states that, globally, there are around 280 million people who suffer from depression. Depression is more common among women compared to men. Globally, 10% of pregnant and post-partum women experience depression every year. WHO states that every year more than 700,000 people die due to suicide. Several studies have shown the potential of CBD in managing depression and anxiety, which has substantially led to improvement in the health condition of the people. Hence, many organizations are incorporating CBD for developing CBD-based products.

Favorable Regulatory Framework

With the growing demand for CBD-based products, there has been consideration within the regulatory bodies such as FDA, to improve and bring new regulatory pathways to support the ethical and safe use of CBD-based products in the healthcare industry. In January 2023, the Food and Drug Administration in the United States announced that it is now re-evaluating the regulatory framework for goods containing cannabidiol. The FDA has determined that the current regulatory frameworks for foods and supplements do not apply to CBD and that a new regulatory approach is required to initiate a compromise between the requirement for consumer safety and people's desire to have access to CBD products. To create a new cross-agency approach to the regulation of these items, the FDA is ready to collaborate with Congress. This favorable change in the current regulatory systems is expected to accelerate the development of cannabidiol.

Consumption of CBD Oil is Witnessing Significant Demand

Among the form segments, CBD oil segment holds a significant market share in the global cannabidiol market. In comparison with other forms of cannabidiol, CBD oil has vast application areas such as in pain management, epilepsy, nutraceuticals and beauty. CBD oils are legal and easy to access, which makes it highly popular among manufacturers and consumers. Additionally, several leading players are launching CBD oils for various medical purposes in their product portfolio, which is enhancing the growth of the global cannabidiol market. For instance, in September 2023, Aurora Cannabis Inc., a Canada based medical cannabis company announced an expansion of its hemp-derived CBD portfolio in Brazil. The company is all set to launch full-spectrum, single-source 3% CBD oil, to cater to the need of the consumers in Brazil.

Application of CBD in Treating Epilepsy

Among the therapeutic application segment, CBD is widely used for the treatment of epilepsy and thus, the segment holds a significant market share in the overall global cannabidiol market. Cannabidiol has shown promising positive effects in the treatment of epilepsy, especially in certain epileptic syndromes such as Lennox-Gastaut syndrome and Dravet syndrome. Regulatory bodies such as the European Medicines Agency and the U.S. Food and Drug Administration have approved CBD for use in certain epilepsy treatments.

Moreover, key market players are bringing new product launches in this segment to improve the health conditions of the patients, which is further accelerating the growth of the segment. In January 2023, Medical Marijuana, Inc. subsidiary "HempMeds Brasil" successfully launched two new CBD-based products in Brazil to help in the treatment process of epilepsy. HempMeds Brasil is authorized to provide its CBD-based products, under medical prescription to aid in the management of diseases such as epilepsy, Parkinson's, chronic pain, and multiple sclerosis.

North America Dominates Global Cannabidiol Market

North America holds the largest share in global cannabidiol market, due to various factors such as the presence of major manufacturers including Medical Marijuana Inc. and Tilray Inc., increased acceptance among healthcare providers and people regarding using CBD-based products for medical conditions such as anxiety, depression, epilepsy, and pain management driving high demand for cannabidiol. Additionally, favorable laws regarding the usage of CBD products in most of the countries in North America are enhancing the growth of the market.

Medical Marijuana Inc., stated that in the United States, there are around 33 states, that have legalized safe usage of marijuana and there are more states that are expected to receive permission to legalize cannabinoid usage in the future. Consequently, along with the re-formation of federal law, it is expected that North America will further undergo tremendous growth in the cannabidiol market and will maintain its leadership in the forecast period as well.

Future Market Scenario (2024 - 2031F)

The global cannabidiol market is expected to grow in the future due to multiple factors. The increasing prevalence of anxiety and depression among the population has enhanced the company's focus in developing CBD-based products that can help with relieving mental stress among the users. Increased acceptance among healthcare providers regarding the capabilities of CBD in the treatment of anxiety, depression, and epilepsy has enabled pharmaceutical companies to increase investments in the market. There has been a surge in research and development activities in the market to further explore the potential benefits of CBD in patient treatments. Collaborative ventures among the companies, improved and supportive regulatory framework, and new entrants have spurred growth in the global cannabidiol market. According to an article published in the "Hartford Business Journal" many CBD companies are planning to start their operations in 2023 and 2024. Along with it, new retailers, manufacturers, and products are expected to enter the cannabidiol market, which will further assist in driving the market growth.

Key Players Landscape and Outlook

In cannabidiol market, several pharmaceutical companies are consistently establishing strategic partnerships, and distribution agreements, which play a pivotal role in driving the demand for cannabidiol products. These partnerships enable firms to gain informative insights regarding the market, take advantage of each other's resources, markets, and technologies, and invest in research and development activities to bring advancements in the market. Distribution agreements enable companies to broaden their market presence at a global level. These collaborative initiatives promote innovation, expertise product development and contribute to the enduring and robust growth of the global market.

For instance, in August 2023, Medical Marijuana, Inc., announced that Kannaway, which is its subsidiary, completed acquisition of a Japan based network marketing company "EXfuse, LLC, dba KZ1". The acquisition will expand the company's business in Japan and the KZ1's premium products such as nootropics-based products enhancing the company's CBD product portfolio. The partnership further aims to bring innovative product launches in their various business segments such as natural health, beauty, and CBD products.

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Cannabidiol Market Outlook, 2017-2031F

  • 4.1.Market Size & Forecast
    • 4.1.1.By Value
    • 4.1.2.By Volume
  • 4.2.By Species
    • 4.2.1.Indica
    • 4.2.2.Sativa
    • 4.2.3.Hybrid
  • 4.3.By Route of Administration
    • 4.3.1.Oral
    • 4.3.2.Topical
    • 4.3.3.Others
  • 4.4.By Form
    • 4.4.1.Oils
    • 4.4.2.Capsules
    • 4.4.3.Tinctures
  • 4.5.By Therapeutic Application
    • 4.5.1.Cancer
    • 4.5.2.Migraine
    • 4.5.3.Epilepsy
    • 4.5.4.Anxiety and Depression
    • 4.5.5.Others
  • 4.6.By End-user
    • 4.6.1.Pharmaceutical Companies
    • 4.6.2.Hospital Pharmacies
    • 4.6.3.Online Pharmacies
    • 4.6.4.Retail Stores
    • 4.6.5.Research and Development Centers
    • 4.6.6.Others
  • 4.7.By Region
    • 4.7.1.North America
    • 4.7.2.Europe
    • 4.7.3.Asia-Pacific
    • 4.7.4.South America
    • 4.7.5.Middle East and Africa
  • 4.8.By Company Market Share (%), 2023

5.Global Cannabidiol Market Outlook, By Region, 2017-2031F

  • 5.1.North America*
    • 5.1.1.Market Size & Forecast
      • 5.1.1.1.By Value
      • 5.1.1.2.By Volume
    • 5.1.2.By Species
      • 5.1.2.1.Indica
      • 5.1.2.2.Sativa
      • 5.1.2.3.Hybrid
    • 5.1.3.By Route of Administration
      • 5.1.3.1.Oral
      • 5.1.3.2.Topical
      • 5.1.3.3.Others
    • 5.1.4.By Form
      • 5.1.4.1.Oils
      • 5.1.4.2.Capsules
      • 5.1.4.3.Tinctures
    • 5.1.5.By Therapeutic Application
      • 5.1.5.1.Cancer
      • 5.1.5.2.Migraine
      • 5.1.5.3.Epilepsy
      • 5.1.5.4.Anxiety and Depression
      • 5.1.5.5.Others
    • 5.1.6.By End-user
      • 5.1.6.1.Pharmaceutical Companies
      • 5.1.6.2.Hospital Pharmacies
      • 5.1.6.3.Online Pharmacies
      • 5.1.6.4.Retail Stores
      • 5.1.6.5.Research and Development Centers
      • 5.1.6.6.Others
    • 5.1.7.United States*
      • 5.1.7.1.Market Size & Forecast
      • 5.1.7.1.1.By Value
      • 5.1.7.1.2.By Volume
      • 5.1.7.2.By Species
      • 5.1.7.2.1.Indica
      • 5.1.7.2.2.Sativa
      • 5.1.7.2.3.Hybrid
      • 5.1.7.3.By Route of Administration
      • 5.1.7.3.1.Oral
      • 5.1.7.3.2.Topical
      • 5.1.7.3.3.Others
      • 5.1.7.4.By Form
      • 5.1.7.4.1.Oils
      • 5.1.7.4.2.Capsules
      • 5.1.7.4.3.Tinctures
      • 5.1.7.5.By Therapeutic Application
      • 5.1.7.5.1.Cancer
      • 5.1.7.5.2.Migraine
      • 5.1.7.5.3.Epilepsy
      • 5.1.7.5.4.Anxiety and Depression
      • 5.1.7.5.5.Others
      • 5.1.7.6.By End-user
      • 5.1.7.6.1.Pharmaceutical Companies
      • 5.1.7.6.2.Hospital Pharmacies
      • 5.1.7.6.3.Online Pharmacies
      • 5.1.7.6.4.Retail Pharmacies
      • 5.1.7.6.5.Research and Development Centers
      • 5.1.7.6.6.Others
    • 5.1.8.Canada
    • 5.1.9.Mexico

All segments will be provided for all regions and countries covered

  • 5.2.Europe
    • 5.2.1.Germany
    • 5.2.2.France
    • 5.2.3.Italy
    • 5.2.4.United Kingdom
    • 5.2.5.Netherlands
    • 5.2.6.Spain
    • 5.2.7.Turkey
    • 5.2.8.Poland
  • 5.3.Asia-Pacific
    • 5.3.1.India
    • 5.3.2.China
    • 5.3.3.Australia
    • 5.3.4.Vietnam
    • 5.3.5.South Korea
  • 5.4.South America
    • 5.4.1.Brazil
    • 5.4.2.Argentina
  • 5.5.Middle East & Africa
    • 5.5.1.South Africa

6.Market Mapping, 2023

  • 6.1.By Species
  • 6.2.By Route of Administration
  • 6.3.By Form
  • 6.4.By Therapeutic Application
  • 6.5.By End-user
  • 6.6.By Region

7.Macro Environment and Industry Structure

  • 7.1.Demand Supply Analysis
  • 7.2.Import Export Analysis
  • 7.3.Value Chain Analysis
  • 7.4.PESTEL Analysis
    • 7.4.1.Political Factors
    • 7.4.2.Economic System
    • 7.4.3.Social Implications
    • 7.4.4.Technological Advancements
    • 7.4.5.Environmental Impacts
    • 7.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5.Porter's Five Forces Analysis
    • 7.5.1.Supplier Power
    • 7.5.2.Buyer Power
    • 7.5.3.Substitution Threat
    • 7.5.4.Threat from New Entrant
    • 7.5.5.Competitive Rivalry

8.Market Dynamics

  • 8.1.Growth Drivers
  • 8.2.Growth Inhibitors (Challenges and Restraints)

9.Regulatory Framework and Innovation

  • 9.1.Clinical Trials
  • 9.2.Patent Landscape
  • 9.3.Regulatory Approvals
  • 9.4.Innovations/Emerging Technologies

10.Key Players Landscape

  • 10.1.Competition Matrix of Top Five Market Leaders
  • 10.2.Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4.SWOT Analysis (For Five Market Players)
  • 10.5.Patent Analysis (If Applicable)

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

  • 13.1.Charlotte's Web, Inc.
    • 13.1.1.Company Details
    • 13.1.2.Key Management Personnel
    • 13.1.3.Products & Services
    • 13.1.4.Financials (As reported)
    • 13.1.5.Key Market Focus & Geographical Presence
    • 13.1.6.Recent Developments
  • 13.2.Medical Marijuana, Inc.
  • 13.3.Jazz Pharmaceuticals plc.
  • 13.4.Aurora Cannabis Inc.
  • 13.5.Hemp Synergistics LLC
  • 13.6.Canopy Growth Corporation
  • 13.7.Isodiol International Inc.
  • 13.8.Gaia Botanicals, LLC, d/b/a Bluebird Botanicals
  • 13.9.CV Sciences, Inc.
  • 13.10.High Tide Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14.Strategic Recommendations

15.About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1.Global Cannabidiol Market, By Value, In USD Billion, 2017-2031F
  • Figure 2.Global Cannabidiol Market, By Volume, In Million Units, 2017-2031F
  • Figure 3.Global Cannabidiol Market Share (%), By Species, 2017-2031F
  • Figure 4.Global Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
  • Figure 5.Global Cannabidiol Market Share (%), By Form, 2017-2031F
  • Figure 6.Global Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
  • Figure 7.Global Cannabidiol Market Share (%), By End-user, 2017-2031F
  • Figure 8.Global Cannabidiol Market Share (%), By Region, 2017-2031F
  • Figure 9.North America Cannabidiol Market, By Value, In USD Billion, 2017-2031F
  • Figure 10.North America Cannabidiol Market, By Volume, In Million Units, 2017-2031F
  • Figure 11.North America Cannabidiol Market Share (%), By Species, 2017-2031F
  • Figure 12.North America Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
  • Figure 13.North America Cannabidiol Market Share (%), By Form, 2017-2031F
  • Figure 14.North America Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
  • Figure 15.North America Cannabidiol Market Share (%), By End-user, 2017-2031F
  • Figure 16.North America Cannabidiol Market Share (%), By Country, 2017-2031F
  • Figure 17.United States Cannabidiol Market, By Value, In USD Billion, 2017-2031F
  • Figure 18.United States Cannabidiol Market, By Volume, In Million Units, 2017-2031F
  • Figure 19.United States Cannabidiol Market Share (%), By Species, 2017-2031F
  • Figure 20.United States Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
  • Figure 21.United States Cannabidiol Market Share (%), By Form, 2017-2031F
  • Figure 22.United States Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
  • Figure 23.United States Cannabidiol Market Share (%), By End-user, 2017-2031F
  • Figure 24.Canada Cannabidiol Market, By Value, In USD Billion, 2017-2031F
  • Figure 25.Canada Cannabidiol Market, By Volume, In Million Units, 2017-2031F
  • Figure 26.Canada Cannabidiol Market Share (%), By Species, 2017-2031F
  • Figure 27.Canada Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
  • Figure 28.Canada Cannabidiol Market Share (%), By Form, 2017-2031F
  • Figure 29.Canada Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
  • Figure 30.Canada Cannabidiol Market Share (%), By End-user, 2017-2031F
  • Figure 31.Mexico Cannabidiol Market, By Value, In USD Billion, 2017-2031F
  • Figure 32.Mexico Cannabidiol Market, By Volume, In Million Units, 2017-2031F
  • Figure 33.Mexico Cannabidiol Market Share (%), By Species, 2017-2031F
  • Figure 34.Mexico Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
  • Figure 35.Mexico Cannabidiol Market Share (%), By Form, 2017-2031F
  • Figure 36.Mexico Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
  • Figure 37.Mexico Cannabidiol Market Share (%), By End-user, 2017-2031F
  • Figure 38.Europe Cannabidiol Market, By Value, In USD Billion, 2017-2031F
  • Figure 39.Europe Cannabidiol Market, By Volume, In Million Units, 2017-2031F
  • Figure 40.Europe Cannabidiol Market Share (%), By Species, 2017-2031F
  • Figure 41.Europe Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
  • Figure 42.Europe Cannabidiol Market Share (%), By Form, 2017-2031F
  • Figure 43.Europe Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
  • Figure 44.Europe Cannabidiol Market Share (%), By End-user, 2017-2031F
  • Figure 45.Europe Cannabidiol Market Share (%), By Country, 2017-2031F
  • Figure 46.Germany Cannabidiol Market, By Value, In USD Billion, 2017-2031F
  • Figure 47.Germany Cannabidiol Market, By Volume, In Million Units, 2017-2031F
  • Figure 48.Germany Cannabidiol Market Share (%), By Species, 2017-2031F
  • Figure 49.Germany Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
  • Figure 50.Germany Cannabidiol Market Share (%), By Form, 2017-2031F
  • Figure 51.Germany Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
  • Figure 52.Germany Cannabidiol Market Share (%), By End-user, 2017-2031F
  • Figure 53.France Cannabidiol Market, By Value, In USD Billion, 2017-2031F
  • Figure 54.France Cannabidiol Market, By Volume, In Million Units, 2017-2031F
  • Figure 55.France Cannabidiol Market Share (%), By Species, 2017-2031F
  • Figure 56.France Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
  • Figure 57.France Cannabidiol Market Share (%), By Form, 2017-2031F
  • Figure 58.France Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
  • Figure 59.France Cannabidiol Market Share (%), By End-user, 2017-2031F
  • Figure 60.Italy Cannabidiol Market, By Value, In USD Billion, 2017-2031F
  • Figure 61.Italy Cannabidiol Market, By Volume, In Million Units, 2017-2031F
  • Figure 62.Italy Cannabidiol Market Share (%), By Species, 2017-2031F
  • Figure 63.Italy Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
  • Figure 64.Italy Cannabidiol Market Share (%), By Form, 2017-2031F
  • Figure 65.Italy Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
  • Figure 66.Italy Cannabidiol Market Share (%), By End-user, 2017-2031F
  • Figure 67.United Kingdom Cannabidiol Market, By Value, In USD Billion, 2017-2031F
  • Figure 68.United Kingdom Cannabidiol Market, By Volume, In Million Units, 2017-2031F
  • Figure 69.United Kingdom Cannabidiol Market Share (%), By Species, 2017-2031F
  • Figure 70.United Kingdom Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
  • Figure 71.United Kingdom Cannabidiol Market Share (%), By Form, 2017-2031F
  • Figure 72.United Kingdom Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
  • Figure 73.United Kingdom Cannabidiol Market Share (%), By End-user, 2017-2031F
  • Figure 74.Russia Cannabidiol Market, By Value, In USD Billion, 2017-2031F
  • Figure 75.Russia Cannabidiol Market, By Volume, In Million Units, 2017-2031F
  • Figure 76.Russia Cannabidiol Market Share (%), By Species, 2017-2031F
  • Figure 77.Russia Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
  • Figure 78.Russia Cannabidiol Market Share (%), By Form, 2017-2031F
  • Figure 79.Russia Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
  • Figure 80.Russia Cannabidiol Market Share (%), By End-user, 2017-2031F
  • Figure 81.Netherlands Cannabidiol Market, By Value, In USD Billion, 2017-2031F
  • Figure 82.Netherlands Cannabidiol Market, By Volume, In Million Units, 2017-2031F
  • Figure 83.Netherlands Cannabidiol Market Share (%), By Species, 2017-2031F
  • Figure 84.Netherlands Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
  • Figure 85.Netherlands Cannabidiol Market Share (%), By Form, 2017-2031F
  • Figure 86.Netherlands Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
  • Figure 87.Netherlands Cannabidiol Market Share (%), By End-user, 2017-2031F
  • Figure 88.Spain Cannabidiol Market, By Value, In USD Billion, 2017-2031F
  • Figure 89.Spain Cannabidiol Market, By Volume, In Million Units, 2017-2031F
  • Figure 90.Spain Cannabidiol Market Share (%), By Species, 2017-2031F
  • Figure 91.Spain Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
  • Figure 92.Spain Cannabidiol Market Share (%), By Form, 2017-2031F
  • Figure 93.Spain Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
  • Figure 94.Spain Cannabidiol Market Share (%), By End-user, 2017-2031F
  • Figure 95.Turkey Cannabidiol Market, By Value, In USD Billion, 2017-2031F
  • Figure 96.Turkey Cannabidiol Market, By Volume, In Million Units, 2017-2031F
  • Figure 97.Turkey Cannabidiol Market Share (%), By Species, 2017-2031F
  • Figure 98.Turkey Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
  • Figure 99.Turkey Cannabidiol Market Share (%), By Form, 2017-2031F
  • Figure 100.Turkey Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
  • Figure 101.Turkey Cannabidiol Market Share (%), By End-user, 2017-2031F
  • Figure 102.Poland Cannabidiol Market, By Value, In USD Billion, 2017-2031F
  • Figure 103.Poland Cannabidiol Market, By Volume, In Million Units, 2017-2031F
  • Figure 104.Poland Cannabidiol Market Share (%), By Species, 2017-2031F
  • Figure 105.Poland Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
  • Figure 106.Poland Cannabidiol Market Share (%), By Form, 2017-2031F
  • Figure 107.Poland Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
  • Figure 108.Poland Cannabidiol Market Share (%), By End-user, 2017-2031F
  • Figure 109.South America Cannabidiol Market, By Value, In USD Billion, 2017-2031F
  • Figure 110.South America Cannabidiol Market, By Volume, In Million Units, 2017-2031F
  • Figure 111.South America Cannabidiol Market Share (%), By Species, 2017-2031F
  • Figure 112.South America Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
  • Figure 113.South America Cannabidiol Market Share (%), By Form, 2017-2031F
  • Figure 114.South America Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
  • Figure 115.South America Cannabidiol Market Share (%), By End-user, 2017-2031F
  • Figure 116.South America Cannabidiol Market Share (%), By Country, 2017-2031F
  • Figure 117.Brazil Cannabidiol Market, By Value, In USD Billion, 2017-2031F
  • Figure 118.Brazil Cannabidiol Market, By Volume, In Million Units, 2017-2031F
  • Figure 119.Brazil Cannabidiol Market Share (%), By Species, 2017-2031F
  • Figure 120.Brazil Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
  • Figure 121.Brazil Cannabidiol Market Share (%), By Form, 2017-2031F
  • Figure 122.Brazil Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
  • Figure 123.Brazil Cannabidiol Market Share (%), By End-user, 2017-2031F
  • Figure 124.Argentina Cannabidiol Market, By Value, In USD Billion, 2017-2031F
  • Figure 125.Argentina Cannabidiol Market, By Volume, In Million Units, 2017-2031F
  • Figure 126.Argentina Cannabidiol Market Share (%), By Species, 2017-2031F
  • Figure 127.Argentina Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
  • Figure 128.Argentina Cannabidiol Market Share (%), By Form, 2017-2031F
  • Figure 129.Argentina Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
  • Figure 130.Argentina Cannabidiol Market Share (%), By End-user, 2017-2031F
  • Figure 131.Asia-Pacific Cannabidiol Market, By Value, In USD Billion, 2017-2031F
  • Figure 132.Asia-Pacific Cannabidiol Market, By Volume, In Million Units, 2017-2031F
  • Figure 133.Asia-Pacific Cannabidiol Market Share (%), By Species, 2017-2031F
  • Figure 134.Asia-Pacific Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
  • Figure 135.Asia-Pacific Cannabidiol Market Share (%), By Form, 2017-2031F
  • Figure 136.Asia-Pacific Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
  • Figure 137.Asia- Pacific Cannabidiol Market Share (%), By End-user, 2017-2031F
  • Figure 138.Asia-Pacific Cannabidiol Market Share (%), By Country, 2017-2031F
  • Figure 139.India Cannabidiol Market, By Value, In USD Billion, 2017-2031F
  • Figure 140.India Cannabidiol Market, By Volume, In Million Units, 2017-2031F
  • Figure 141.India Cannabidiol Market Share (%), By Species, 2017-2031F
  • Figure 142.India Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
  • Figure 143.India Cannabidiol Market Share (%), By Form, 2017-2031F
  • Figure 144.India Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
  • Figure 145.India Cannabidiol Market Share (%), By End-user, 2017-2031F
  • Figure 146.China Cannabidiol Market, By Value, In USD Billion, 2017-2031F
  • Figure 147.China Cannabidiol Market, By Volume, In Million Units, 2017-2031F
  • Figure 148.China Cannabidiol Market Share (%), By Species, 2017-2031F
  • Figure 149.China Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
  • Figure 150.China Cannabidiol Market Share (%), By Form, 2017-2031F
  • Figure 151.China Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
  • Figure 152.China Cannabidiol Market Share (%), By End-user, 2017-2031F
  • Figure 153.Japan Cannabidiol Market, By Value, In USD Billion, 2017-2031F
  • Figure 154.Japan Cannabidiol Market, By Volume, In Million Units, 2017-2031F
  • Figure 155.Japan Cannabidiol Market Share (%), By Species, 2017-2031F
  • Figure 156.Japan Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
  • Figure 157.Japan Cannabidiol Market Share (%), By Form, 2017-2031F
  • Figure 158.Japan Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
  • Figure 159.Japan Cannabidiol Market Share (%), By End-user, 2017-2031F
  • Figure 160.Australia Cannabidiol Market, By Value, In USD Billion, 2017-2031F
  • Figure 161.Australia Cannabidiol Market, By Volume, In Million Units, 2017-2031F
  • Figure 162.Australia Cannabidiol Market Share (%), By Species, 2017-2031F
  • Figure 163.Australia Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
  • Figure 164.Australia Cannabidiol Market Share (%), By Form, 2017-2031F
  • Figure 165.Australia Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
  • Figure 166.Australia Cannabidiol Market Share (%), By End-user, 2017-2031F
  • Figure 167.Vietnam Cannabidiol Market, By Value, In USD Billion, 2017-2031F
  • Figure 168.Vietnam Cannabidiol Market, By Volume, In Million Units, 2017-2031F
  • Figure 169.Vietnam Cannabidiol Market Share (%), By Species, 2017-2031F
  • Figure 170.Vietnam Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
  • Figure 171.Vietnam Cannabidiol Market Share (%), By Form, 2017-2031F
  • Figure 172.Vietnam Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
  • Figure 173.Vietnam Cannabidiol Market Share (%), By End-user, 2017-2031F
  • Figure 174.South Korea Cannabidiol Market, By Value, In USD Billion, 2017-2031F
  • Figure 175.South Korea Cannabidiol Market, By Volume, In Million Units, 2017-2031F
  • Figure 176.South Korea Cannabidiol Market Share (%), By Species, 2017-2031F
  • Figure 177.South Korea Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
  • Figure 178.South Korea Cannabidiol Market Share (%), By Form, 2017-2031F
  • Figure 179.South Korea Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
  • Figure 180.South Korea Cannabidiol Market Share (%), By End-user, 2017-2031F
  • Figure 181.Indonesia Cannabidiol Market, By Value, In USD Billion, 2017-2031F
  • Figure 182.Indonesia Cannabidiol Market, By Volume, In Million Units, 2017-2031F
  • Figure 183.Indonesia Cannabidiol Market Share (%), By Species, 2017-2031F
  • Figure 184.Indonesia Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
  • Figure 185.Indonesia Cannabidiol Market Share (%), By Form, 2017-2031F
  • Figure 186.Indonesia Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
  • Figure 187.Indonesia Cannabidiol Market Share (%), By End-user, 2017-2031F
  • Figure 188.Philippines Cannabidiol Market, By Value, In USD Billion, 2017-2031F
  • Figure 189.Philippines Cannabidiol Market, By Volume, In Million Units, 2017-2031F
  • Figure 190.Philippines Cannabidiol Market Share (%), By Species, 2017-2031F
  • Figure 191.Philippines Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
  • Figure 192.Philippines Cannabidiol Market Share (%), By Form, 2017-2031F
  • Figure 193.Philippines Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
  • Figure 194.Philippines Cannabidiol Market Share (%), By End-user, 2017-2031F
  • Figure 195.Middle East & Africa Cannabidiol Market, By Value, In USD Billion, 2017-2031F
  • Figure 196.Middle East & Africa Cannabidiol Market, By Volume, In Million Units, 2017-2031F
  • Figure 197.Middle East & Africa Cannabidiol Market Share (%), By Species, 2017-2031F
  • Figure 198.Middle East & Africa Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
  • Figure 199.Middle East & Africa Cannabidiol Market Share (%), By Form, 2017-2031F
  • Figure 200.Middle East & Africa Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
  • Figure 201.Middle East & Africa Cannabidiol Market Share (%), By End-user, 2017-2031F
  • Figure 202.Middle East & Africa Cannabidiol Market Share (%), By Country, 2017-2031F
  • Figure 203.Saudi Arabia Cannabidiol Market, By Value, In USD Billion, 2017-2031F
  • Figure 204.Saudi Arabia Cannabidiol Market, By Volume, In Million Units, 2017-2031F
  • Figure 205.Saudi Arabia Cannabidiol Market Share (%), By Species, 2017-2031F
  • Figure 206.Saudi Arabia Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
  • Figure 207.Saudi Arabia Cannabidiol Market Share (%), By Form, 2017-2031F
  • Figure 208.Saudi Arabia Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
  • Figure 209.Saudi Arabia Cannabidiol Market Share (%), By End-user, 2017-2031F
  • Figure 210.UAE Cannabidiol Market, By Value, In USD Billion, 2017-2031F
  • Figure 211.UAE Cannabidiol Market, By Volume, In Million Units, 2017-2031F
  • Figure 212.UAE Cannabidiol Market Share (%), By Species, 2017-2031F
  • Figure 213.UAE Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
  • Figure 214.UAE Cannabidiol Market Share (%), By Form, 2017-2031F
  • Figure 215.UAE Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
  • Figure 216.UAE Cannabidiol Market Share (%), By End-user, 2017-2031F
  • Figure 217.South Africa Cannabidiol Market, By Value, In USD Billion, 2017-2031F
  • Figure 218.South Africa Cannabidiol Market, By Volume, In Million Units, 2017-2031F
  • Figure 219.South Africa Cannabidiol Market Share (%), By Species, 2017-2031F
  • Figure 220.South Africa Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
  • Figure 221.South Africa Cannabidiol Market Share (%), By Form, 2017-2031F
  • Figure 222.South Africa Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
  • Figure 223.South Africa Cannabidiol Market Share (%), By End-user, 2017-2031F
  • Figure 224.By Species Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 225.By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 226.By Form Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 227.By Therapeutical Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 228.By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 229.By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023